Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland
- PMID: 19951962
- DOI: 10.1093/eurjhf/hfp160
Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland
Abstract
Aims: Heart failure (HF) and chronic obstructive pulmonary disease (COPD) frequently coexist and present major challenges to healthcare providers. The epidemiology, consultation rate, and treatment of patients with HF and COPD in primary care are ill-defined.
Methods and results: This was an analysis of cross-sectional data from 61 primary care practices (377 439 patients) participating in the Scottish Continuous Morbidity Recording scheme. The prevalence of COPD in patients with HF increased from 19.8% in 1999 to 23.8% in 2004. In 2004, the prevalence was similar in men and women (24.8% vs. 22.9%, P = 0.09), increased with age up to 75 years, and increased with greater socioeconomic deprivation (most deprived 31.3% vs. least deprived 18.6%, P = 0.01). Contact rates for HF or COPD in those with both conditions were greater than disease-specific contact rates in patients with either condition alone. Although overall beta-blocker prescribing increased over time; the adjusted odds of beta-blocker prescription in patients with COPD was low and failed to improve [odds ratio 0.30 (0.28-0.32), P < 0.001]. In 2004, only 18% of individuals with HF and COPD were prescribed beta-blockers vs. 41% in those without COPD.
Conclusion: Chronic obstructive pulmonary disease is a frequent comorbidity in patients with HF and represents a significant healthcare burden to primary care. Although beta-blocker prescribing in the community has increased, less than a fifth of patients with HF and COPD received beta-blockers.
Similar articles
-
National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland.Heart. 2004 Oct;90(10):1129-36. doi: 10.1136/hrt.2003.029553. Heart. 2004. PMID: 15367505 Free PMC article.
-
Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.J Am Coll Cardiol. 2007 Jan 16;49(2):171-80. doi: 10.1016/j.jacc.2006.08.046. Epub 2006 Dec 29. J Am Coll Cardiol. 2007. PMID: 17222727 Review.
-
Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial.Eur J Heart Fail. 2009 Jul;11(7):684-90. doi: 10.1093/eurjhf/hfp066. Epub 2009 May 21. Eur J Heart Fail. 2009. PMID: 19460848 Clinical Trial.
-
Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality.Curr Opin Pulm Med. 2010 Mar;16(2):106-11. doi: 10.1097/MCP.0b013e328335dc90. Curr Opin Pulm Med. 2010. PMID: 20042977 Review.
-
[Impact of comorbidities for the treatment of heart failure].Rev Prat. 2010 Sep 20;60(7):955-9. Rev Prat. 2010. PMID: 21033494 French.
Cited by
-
Predicting Trends in Dyspnea and Fatigue in Heart Failure Patients' Outcomes.Acta Cardiol Sin. 2013 Nov;29(6):488-95. Acta Cardiol Sin. 2013. PMID: 27122749 Free PMC article.
-
Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges.ESC Heart Fail. 2015 Sep;2(3):103-107. doi: 10.1002/ehf2.12055. Epub 2015 Jul 31. ESC Heart Fail. 2015. PMID: 27708851 Free PMC article.
-
The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit.Multidiscip Respir Med. 2014 Feb 4;9(1):8. doi: 10.1186/2049-6958-9-8. Multidiscip Respir Med. 2014. PMID: 24495706 Free PMC article.
-
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.J Am Heart Assoc. 2021 Feb 16;10(4):e019238. doi: 10.1161/JAHA.120.019238. Epub 2021 Jan 30. J Am Heart Assoc. 2021. PMID: 33522249 Free PMC article. Clinical Trial.
-
Pharmacological Management of Elderly Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Room for Speculation?Drugs Aging. 2016 Jun;33(6):375-85. doi: 10.1007/s40266-016-0368-z. Drugs Aging. 2016. PMID: 27138954 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous